The pivotal role of central sensitization in long COVID, fibromyalgia and myalgic encephalomyelitis/chronic fatigue syndrome.

IF 3.4 2区医学 Q2 CLINICAL NEUROLOGY

Expert Review of Neurotherapeutics Pub Date : 2025-06-13 DOI:10.1080/14737175.2025.2516097

Don L Goldenberg

{"title":"The pivotal role of central sensitization in long COVID, fibromyalgia and myalgic encephalomyelitis/chronic fatigue syndrome.","authors":"Don L Goldenberg","doi":"10.1080/14737175.2025.2516097","DOIUrl":null,"url":null,"abstract":"Introduction: Long COVID is a condition characterized by persistent unexplained symptoms following COVID-19 infection. These symptoms are not related to another disease or organ damage and are similar to those in fibromyalgia and myslgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).Areas covered: The similar clinical and pathophysiological features and management of long COVID, fibromyalgia and ME/CFS are explored from the unifying framework of central sensitivity syndromes. The article is based on a literature search utilizing PubMed for content published between 2021 and 1 May 2025, using search terms: long COVID, long COVID syndrome, post-COVID-19, post-acute SARS-CoV-2, fibromyalgia, ME/CFS, post-exertional malaise and central sensitization.Expert opinion: Once long COVID is redefined to exclude patients with well-defined organ disease, it fits best as a model of central sensitization. Long COVID is a single syndrome, rather than many distinct diseases. Optimal management of long COVID and similar central sensitivity syndromes should include personalized care with a primary care led-multidisciplinary team.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-17"},"PeriodicalIF":3.4000,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Neurotherapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737175.2025.2516097","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Long COVID is a condition characterized by persistent unexplained symptoms following COVID-19 infection. These symptoms are not related to another disease or organ damage and are similar to those in fibromyalgia and myslgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

Areas covered: The similar clinical and pathophysiological features and management of long COVID, fibromyalgia and ME/CFS are explored from the unifying framework of central sensitivity syndromes. The article is based on a literature search utilizing PubMed for content published between 2021 and 1 May 2025, using search terms: long COVID, long COVID syndrome, post-COVID-19, post-acute SARS-CoV-2, fibromyalgia, ME/CFS, post-exertional malaise and central sensitization.

Expert opinion: Once long COVID is redefined to exclude patients with well-defined organ disease, it fits best as a model of central sensitization. Long COVID is a single syndrome, rather than many distinct diseases. Optimal management of long COVID and similar central sensitivity syndromes should include personalized care with a primary care led-multidisciplinary team.

查看原文本刊更多论文

中枢致敏在长冠状病毒、纤维肌痛和肌痛性脑脊髓炎/慢性疲劳综合征中的关键作用。

长COVID是指COVID-19感染后持续出现无法解释的症状。这些症状与其他疾病或器官损伤无关，与纤维肌痛和迷迷性脑脊髓炎/慢性疲劳综合征（ME/CFS）相似。涵盖领域：从中枢敏感性综合征的统一框架探讨长冠状病毒病、纤维肌痛和ME/CFS的相似临床和病理生理特征及处理。本文基于PubMed对2021年至2025年5月1日期间发表的内容进行的文献检索，检索词为：长COVID、长COVID综合征、后COVID、后急性SARS-CoV-2、纤维肌痛、ME/CFS、劳累后不适和中枢致敏。专家意见：一旦长冠状病毒被重新定义以排除有明确器官疾病的患者，它就最适合作为中枢致敏的模型。新冠肺炎是一种单一的综合征，而不是许多不同的疾病。对长冠状病毒和类似中枢敏感性综合征的最佳管理应包括由初级保健领导的多学科团队进行个性化护理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Neurotherapeutics Medicine-Neurology (clinical)

CiteScore

7.00

自引率

2.30%

发文量

审稿时长

4-8 weeks

期刊介绍： Expert Review of Neurotherapeutics (ISSN 1473-7175) provides expert reviews on the use of drugs and medicines in clinical neurology and neuropsychiatry. Coverage includes disease management, new medicines and drugs in neurology, therapeutic indications, diagnostics, medical treatment guidelines and neurological diseases such as stroke, epilepsy, Alzheimer''s and Parkinson''s. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points